Canon BioMedical announced today that it has signed an exclusive distribution agreement with Molecular Biology Systems (MBS) B.V. to market and sell their NEXTGENPCR instrument, consumables, and accessories in the USA and Canada.
Under the terms of the agreement, Canon BioMedical will distribute the NEXTGENPCR instrument, consumables, and associated accessories. Next-generation PCR, described by MBS as the first real advance in thermal cycling in 15 years, reduces the time-consuming DNA amplification procedure from hours to just minutes. For example, a three-step, 30-cycle protocol to amplify a 100-base pair fragment can be completed in less than two minutes.
Dennis Snyder, Senior Director of Global Commercial Operations for Canon BioMedical reports, “Canon BioMedical is committed to empowering the biomedical research community by marketing innovative technologies.” Snyder added, “MBS shares in our commitment to high-quality products that improve the laboratory experience. Researchers want answers as fast as possible, and offering the NEXTGENPCR products to our customers will shorten their protocols without requiring them to change their procedures.”
Gert de Vos, the CEO and founder of MBS, concluded, “Canon BioMedical will be a great partner for us. They prioritize their customers’ experiences not only through their products but also with the service and support that they provide. We believe that Canon BioMedical can make NEXTGENPCR a market leader in the United States and Canada. We are happy that Canon BioMedical recognizes the innovation, quality design, and reduced environmental impact of our NEXTGENPCR products.”
Canon BioMedical will initially distribute the NEXTGENPCR instrument in the USA. The thermocycler will be introduced at multiple upcoming conferences.